Last reviewed · How we verify
NCT06989515
Clinical Outcomes and Ejaculatory Function in BPO Patients Treated With Silodosin
trial in Benign Prostate Obstruction (BPO) in 100 participants. Not yet recruiting.
1 March 2026
Quick facts
| Lead sponsor | Marmara University |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 15 June 2025 |
| Primary completion | 1 March 2026 |
| Estimated completion | 12 June 2026 |
Conditions studied
- Benign Prostate Obstruction (BPO) — all drugs for Benign Prostate Obstruction (BPO) →
- Lower Urinary Tract Symptom — all drugs for Lower Urinary Tract Symptom →
- Ejaculatory Dysfunction — all drugs for Ejaculatory Dysfunction →
- Anejaculation — all drugs for Anejaculation →
Sponsor
Marmara University
Who can join
40 and older, male only, with Benign Prostate Obstruction (BPO) or Lower Urinary Tract Symptom. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This observational study aims to evaluate the relationship between silodosin-induced anejaculation and clinical outcomes in male patients with benign prostatic obstruction (BPO). Silodosin is a commonly used alpha-blocker for lower urinary tract symptoms (LUTS). However, it may cause ejaculatory dysfunction, particularly anejaculation. In this study, patients receiving silodosin for the first time will be grouped based on whether they experience anejaculation or not. Treatment response will be assessed using urinary flow rate, post-void residual urine, and International Prostate Symptom Score (IPSS). Sexual function will be evaluated using the International Index of Erectile Function-5 (IIEF-5) before and after treatment. The study aims to explore whether the presence of anejaculation is associated with improved symptom relief or differences in sexual health.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06989515
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Marmara University trials
Trials by the same sponsor.
- NCT07533734 — The Effects of an Augmented Reality-Based Mirror Therapy System in Patients With Stroke · NA · not yet recruiting
- NCT07474181 — Simulation-Based Training for Urinary Catheterization Skills in Nursing Students · NA · not yet recruiting
- NCT07486349 — Shoulder Pericapsular Block Versus Interscalene Block in Arthroscopic Shoulder Surgery · NA · not yet recruiting
- NCT07468110 — Evaluation Of The Relationship Between The Conut Score And Balance And Functional Status In Patients With Chronic Stroke · recruiting
- NCT07468097 — The Impact of Metabolic Status on Pain and Central Sensitization in Women With Lipedema: A Cross-Sectional Observational · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06989515 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Marmara University
- Last refreshed: 5 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06989515.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing